0.030
0.000
(0.00%)
May 24 - Close
CVE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.03 - 0.04 |
| 52 week | 0.03 - 0.16 |
| Open | 0.04 |
| Vol / Avg. | 154,000.00/92,247.00 |
| Mkt cap | 2.50M |
| P/E | - |
| Div/yield | - |
| EPS | -0.05 |
| Shares | 83.21M |
| Beta | 0.88 |
| Inst. own | - |
Events
Jun 13, 2013
Covalon Technologies Ltd Annual and Special Shareholder Meeting
May 31, 2013
Q2 2013 Covalon Technologies Ltd Earnings Release
Mar 25, 2013
Q1 2013 Covalon Technologies Ltd Earnings Release
|
|
Key stats and ratios
| Q3 (Sep '12) | 2012 | |
| Net profit margin | -198.24% | -105.22% |
| Operating margin | -199.89% | -106.49% |
| EBITD margin | - | -87.40% |
| Return on average assets | -111.77% | -52.22% |
| Return on average equity | -179.61% | -77.88% |
| Carbon Disclosure Rating | - | - |
Address
Suite 106, 405 Britannia Road East
MISSISSAUGA, ON L4Z 3E6
Canada
+1-905-5688400 (Phone)
+1-905-5685200 (Fax)
MISSISSAUGA, ON L4Z 3E6
Canada
+1-905-5688400 (Phone)
+1-905-5685200 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Covalon Technologies Ltd. (Covalon) is a medical device and biotechnology commercialization company. The Company is engaged in the business of developing, licensing and selling medical technologies. The Company operates in two segments: Advanced Wound Care and Specialized Medical Device Coatings. Its offices and laboratories are located in Mississauga, Ontario, Canada. Covalon sells its technologies to medical companies and distributors. Covalon�s antimicrobial technologies can be used for applications in areas, such as medical device coatings, wound care products, polymer mixes for extrusion, skin sanitizers, surface sanitizers, cosmetics, consumer products, veterinary applications, and others. Its products include ColActive, ColActive Ag, ColActive Plus, ColActive Plus Ag and CovaClear Ag. The Company�s wholly owned subsidiaries include Covalon Technologies Inc. and COV Healthcare Innovations Corp.
Officers and directors
| Abe Schwartz | Chairman of the Board | |
| Brian E. Pedlar | President, Chief Executive Officer, Interim Chief Financial Officer, Director | |
| Valerio DiTizio | Chief Scientific Officer | |
| Paul Weber | Vice President - Business Development | |
| Martin C. Bernholtz | Independent Director | |
| Joseph Cordiano | Independent Director | |
| Jeffrey A. Mandel | Independent Director | |
| Murray Miller | Independent Director |